Clinical Trial Update: A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Adenovirus Serotype 26 Based Respiratory Syncytial Virus Pre-fusion (Ad26.RSV.Pre-F) Vaccine in RSV-Seronegative Toddlers 12 to 24 Months of Age [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update reports results from Phase 1/2 studies assessing safety, reactogenicity, and immunogenicity of the Ad26.RSV.Pre-F vaccine in RSV-sero…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syncytial Virus Infection

Drugs mentioned

• Ad26.RSV.Pre-F (Adenovirus serotype 26-based Respiratory Syncytial Virus Pre-Fusion vaccine)

Snippet

Sponsor: Janssen Vaccines & Prevention B.V. | Conditions: Respiratory Syncytial Virus | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2022-11-30